|
|
Volumn 3 Suppl 1, Issue , 2002, Pages
|
|
Challenges in the management of Burkitt's lymphoma.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALLOPURINOL;
ANAVACYM PROTOCOL;
ANTINEOPLASTIC AGENT;
BLEOMYCIN;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DEXAMETHASONE;
DOXORUBICIN;
ENZYME INHIBITOR;
ETOPOSIDE;
FOLINIC ACID;
IFOSFAMIDE;
IVAC PROTOCOL;
M BACOD PROTOCOL;
M-BACOD PROTOCOL;
METHOTREXATE;
RASBURICASE;
URATE OXIDASE;
VINCRISTINE;
ADULT;
BURKITT LYMPHOMA;
CLINICAL TRIAL;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
REVIEW;
TIME;
TREATMENT OUTCOME;
VIROLOGY;
ADULT;
ALLOPURINOL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
BLEOMYCIN;
BURKITT LYMPHOMA;
CLINICAL TRIALS;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DEXAMETHASONE;
DOXORUBICIN;
ENZYME INHIBITORS;
ETOPOSIDE;
HIV INFECTIONS;
HUMANS;
IFOSFAMIDE;
LEUCOVORIN;
METHOTREXATE;
TIME FACTORS;
TREATMENT OUTCOME;
URATE OXIDASE;
VINCRISTINE;
MLCS;
MLOWN;
|
|
EID: 0141889623
PISSN: 15269655
EISSN: None
Source Type: Journal
DOI: 10.3816/clm.2002.s.011 Document Type: Review |
|
Times cited : (25)
|
|
References (31)
|
